Google has made a change to how it’s search results are served which will also help to secure it against bots and scrapers. Whether this will have further effect on SEO Tools or if they can use a ...
Replimune Group announced that the U.S. Food and Drug Administration has accepted the resubmission of its Biologics License Application for RP1 in combination with nivolumab, targeting advanced ...
Replimune Group (REPL) has drawn attention after presenting updated clinical data from its IGNYTE phase 2 trial at the ESMO Congress 2025. The study combined RP1 with nivolumab in patients with acral ...
Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...
Investing.com -- Replimune Group Inc (NASDAQ:REPL) stock soared 60% after the U.S. Food and Drug Administration (FDA) accepted the company’s resubmission of a Biologics License Application (BLA) for ...
The fate of a once-promising cancer treatment now looks uncertain at best. The meeting was conducted with U.S. Food and Drug Administration (FDA) officials, and it took place on Tuesday. The subject ...
SAN DIEGO, Aug. 12, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Replimune Group, Inc. (NASDAQ: REPL) ...
On Monday, Replimune Group Inc. (NASDAQ:REPL) is reeling after the FDA unexpectedly rejected its skin cancer treatment, triggering a stock plunge and a wave of investor outrage. Shares fell sharply ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results